Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study comparing effectiveness of caladribine versus fingolimod in the treatment of highly active relapsing multiple sclerosis

Trial Profile

A retrospective study comparing effectiveness of caladribine versus fingolimod in the treatment of highly active relapsing multiple sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms The MERLYN Study

Most Recent Events

  • 26 Apr 2022 Results assessing effectiveness of Cladribine versus Fingolimod in the treatment of highly active Relapsing Multiple Sclerosis presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 06 Apr 2022 New trial record
  • 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top